USPSTF Breast Cancer Screening Guidelines: A Critical Review
This paper critically examines the 2009 United States Preventive Services Task Force (USPSTF) decision to revise breast cancer screening guidelines, raising the recommended age for routine mammography from forty to fifty and scaling back clinical and self breast exams. Drawing on mortality data, organizational positions, and published research, the paper argues that these changes lack sufficient clinical support and place women — particularly minority and low-income populations — at greater risk. It reviews the historical decline in breast cancer mortality since 1990, analyzes potential consequences for insurance coverage and federally funded programs, and concludes that women should continue following the previous guidelines until robust clinical evidence justifies the change.
- Introduction: Overview of USPSTF 2009 guideline change and its stakes
- History of Breast Cancer Screening: Screening history and mortality decline since 1990
- Analysis of the New Guidelines: Critique of statistical basis for guideline revision
- Impact on the Healthcare Discipline: Effects on patient behavior and high-risk populations
- Future Implications: Insurance coverage and funding scenarios under new rules
- Conclusion: Call to retain prior guidelines pending clinical evidence
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its argument in specific mortality statistics — such as the two percent annual decline in breast cancer deaths since 1990 — giving the critique measurable, concrete weight rather than relying solely on opinion.
- It broadens the scope of impact by addressing health equity, specifically noting that minority women and low-income households face disproportionate risk under the revised guidelines, which strengthens the public-health dimension of the argument.
- The paper balances institutional voices (USPSTF, ACS, Susan G. Komen) against peer-reviewed sources, showing awareness of how authority and evidence interact in health policy debates.
Key academic technique demonstrated
The paper uses a policy critique structure: it states the change, reviews the historical context that made prior policy effective, identifies the evidentiary gap behind the revision, and projects future harms. This cause-and-effect reasoning across a past–present–future timeline is a strong analytical technique for evaluating health policy decisions.
Structure breakdown
The paper is organized into five substantive sections following the introduction: a historical overview of screening since 1990, a critical analysis of the USPSTF decision, a discussion of how the changes affect healthcare practice, a forward-looking section on insurance and funding scenarios, and a conclusion that synthesizes the argument and calls for return to prior guidelines. Each section builds logically on the last, moving from evidence to impact to recommendation.
Introduction
New breast cancer screening guidelines represent an important topic because they affect all women. Not only do they affect women directly, but they also affect their children, other family members, and friends. Breast cancer is a serious disease, and the new guidelines appear to have taken us a step backwards rather than forward in our efforts to continue decreasing the mortality rate. The new guidelines suggest that women receive their first breast exam at the age of fifty instead of forty. Specifically, the new breast screening guidelines established by the United States Preventive Services Task Force (USPSTF) determined in November of 2009 that routine screening should begin at the age of fifty instead of forty, and that clinical as well as self breast exams should be scaled back. The established guideline of a screening every other year for women in their fifties and sixties remained unchanged. (6)
If healthcare providers adhere to these new guidelines, many women in their forties and younger are being placed at risk, since early detection is no longer encouraged as it once was. Breast cancer screening is an effective means of early detection, and in most cases this screening can detect the early stages of cancer even before the patient discovers a small lump while performing a breast self-exam. Breast cancer is one of the leading causes of death in women, and the previous guidelines must be taken seriously. The Susan G. Komen for the Cure organization does not agree with the new guidelines and maintains that the age for the start of breast cancer screening should remain at forty. (1) The USPSTF has also stated that women as well as their physicians should reduce the frequency of breast self-examinations. This does not appear to be a sound recommendation and seems to steer women away from taking charge of their own health. A physician would perform this examination approximately once a year at the time of the patient's annual exam, but in the past, women have been encouraged to perform breast self-examinations at least once a month. These monthly self-examinations could play an extremely important role in early detection. Many women — young and older alike — have discovered small lumps in their breast long before they were due for a mammogram.
It does not make sense to scale back on every aspect of the guidelines. If women are being encouraged to begin regular mammograms at the age of fifty, they most certainly should not be discouraged from performing self-examinations. If all viable detection options are being discouraged simultaneously, this leaves women exposed to the threat of developing breast cancer without discovering it until it is too late. The mortality rate would almost certainly increase, and the USPSTF would then need to revert to recommending the previous guidelines.
This topic warrants attention because of the potential negative impact it can have on early detection and survival rates. Breast cancer can occur in men, but it is rare. The majority of those affected by this disease are women, and therefore women must come together collectively and challenge the new guidelines. Everyone needs to be concerned about how these new guidelines will affect them. Most people have had a mother, sister, aunt, cousin, or other relative who is either a breast cancer survivor or a loved one who has succumbed to the disease.
References
1. Cancer Weekly. Concerned Federal Screening Mammography Guidelines to Limit Access for Younger Women. Susan G. Komen for the Cure. 2010: 1665.
2. Earthtimes.org. Stick with Older Mammography Recommendations, Stanford Experts Say. March 3, 2010 (Press Release from Stanford Hospital & Clinics).
3. Hoppel, Ann M. To screen, and when to screen: the mammography age divide. Clinician Reviews. 2009: 19.12.
4. Journal of the American Academy of Physician Assistants. USPSTF: no routine mammography for women younger than 50 years. 2010; 23.2, p. 66.
5. Mandelblatt, Jeanne, Saha, Somnath, et al. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2003; 139(10): 835–843.
6. Robb-Nicholson, Celeste. A doctor talks about: Screening mammography. Harvard Women's Health Watch. 2010: General Reference Center Gold.
7. Sarff, MaryClare, Schmidt, Katherine, and Vetto, John T. Targeted breast cancer screening in women younger than 40: results from a statewide program. 2008; 195(5): 626–630.
8. Saywell, Robert M. Jr., Champion, Victoria L., Sugg-Skinner, Celette, and Daggy, Joanne. A cost-effectiveness comparison of three tailored interventions to increase mammography screening. Journal of Women's Health. 2004; 13(8): 909–918.
9. Sutton, Sharyn M., Eisner, Ellen J., Bloom, Diane L., and Bloom, Paul N. The mammography guidelines controversy: what do women think? Advances in Consumer Research. 1994; 13: 387–391.
10. Urrea, Jamee. Mammography: testing the changes — survey finds state-run program has scaled back; director cites funding. Lansing State Journal. February 28, 2010.
Create your account
Always verify citation format against your institution’s current style guide requirements.